Malignant meningioma, also known as Grade 3 or anaplastic meningioma, is a rare and aggressive form of brain tumor. Understanding how these tumors are diagnosed is essential for anyone facing symptoms or preparing for treatment decisions. This article walks you through the diagnostic process in clear, simple terms.

Introduction: When to Seek Diagnostic Testing

Malignant meningiomas are uncommon compared to their benign counterparts, but they require prompt attention when symptoms appear. Anyone experiencing persistent or worsening neurological symptoms should consider seeking diagnostic evaluation from a healthcare provider. Because these tumors grow from the protective layers surrounding the brain and spinal cord, called the meninges, they can press on brain tissue and cause various problems depending on where they are located.^[1]

You should consider seeking medical attention if you notice symptoms that don’t go away or get worse over time. Common warning signs include headaches that are more severe in the morning, changes in your vision such as double vision or blurriness, hearing loss, memory problems, muscle weakness, seizures, or changes in your ability to smell. Sometimes symptoms can be subtle at first, which is why it’s important not to dismiss ongoing concerns.^[2]

People over age 65 may find it particularly challenging to recognize symptoms, as they can resemble normal signs of aging. This is one reason why malignant meningiomas can be difficult to diagnose early. If you have risk factors such as prior radiation therapy to the head, a family history of meningiomas, or certain genetic conditions like neurofibromatosis type 2, you should be especially alert to these warning signs.^[1][3]

Grade 3 meningiomas occur more often in males, unlike the more common benign forms which are more frequent in females. These malignant tumors tend to appear in people around 60 years old, and the risk increases with age. High-grade meningiomas are most common in non-Hispanic white people. Knowing your risk profile can help you and your doctor decide when diagnostic testing might be appropriate.^[3]

Diagnostic Methods for Identifying Malignant Meningioma

The diagnostic journey for malignant meningioma typically begins with a thorough physical examination and neurological assessment. Your healthcare provider will perform tests to evaluate your brain and nervous system function. During a neurological exam, the doctor will check things like your balance, coordination, reflexes, muscle strength, sensation, vision, and memory. These tests help identify which part of the brain might be affected by a tumor.^[1]

Because meningiomas grow slowly and may not cause noticeable symptoms until they become large, the physical exam alone may not reveal the problem. This is especially true if you can compensate for balance or coordination problems during a brief office visit. For this reason, imaging tests are essential for confirming the diagnosis.^[1]

Imaging Tests: The Gold Standard

The most important diagnostic tool for identifying a meningioma is medical imaging. Your doctor will typically order either a CT scan (computed tomography) or an MRI (magnetic resonance imaging) of your brain. Both of these tests create detailed pictures of the inside of your head, allowing doctors to see tumors that would otherwise be invisible.^[1][9]

An MRI scan is generally considered the preferred imaging test for diagnosing meningiomas. This test uses powerful magnets and radio waves instead of radiation to create very detailed, cross-sectional images of your brain structures. MRI scans provide clearer pictures of soft tissues compared to CT scans, making them better at showing the exact size, location, and characteristics of a meningioma. During the scan, you’ll lie still inside a large tube-shaped machine for about 30 to 60 minutes. The machine is loud, but you’ll be given ear protection.^[9]

CT scans use X-rays taken from multiple angles to create cross-sectional images of your brain. Sometimes a special dye called contrast dye is injected into your vein before the scan. This dye makes certain tissues show up more clearly in the images, helping doctors see the tumor better. The contrast makes the picture “easier to read” by highlighting blood vessels and abnormal tissue. A CT scan is faster than an MRI and may be used when MRI is not available or if you cannot have an MRI due to metal implants in your body.^[9]

Grade 2 and Grade 3 meningiomas usually appear on an MRI as a mass on the outside lining of the brain tissue. The tumor may or may not brighten up when contrast dye is used. The appearance on imaging can give doctors important clues about whether the tumor is benign or malignant, but imaging alone cannot definitively determine the grade.^[3][10]

Tissue Diagnosis: Confirming the Grade

While imaging tests can show that you have a meningioma, they cannot tell with complete certainty whether it is malignant or benign. To get an accurate diagnosis of the tumor grade, a piece of the tumor tissue must be removed and examined under a microscope. This process is called a biopsy. For meningiomas, the biopsy is usually performed during surgery to remove the tumor, rather than as a separate procedure beforehand.^[3][10]

After tissue is removed during surgery, it is sent to a specialist doctor called a neuropathologist. This doctor examines the tumor cells under a microscope to determine the grade. Meningiomas are classified into three grades based on how the cells look and behave. Grade 1 tumors have slowly growing cells that look relatively normal. Grade 2 tumors, called atypical meningiomas, grow more quickly and have a higher chance of coming back after removal. Grade 3 tumors, called anaplastic or malignant meningiomas, are fast-growing with irregular cells that are likely to invade nearby brain tissue or even spread to other parts of the body.^[3]

One of the most important features that neuropathologists look for when determining the grade is the mitotic count. This refers to the number of cells that are actively dividing when viewed under the microscope. More dividing cells indicate a more aggressive tumor. The neuropathologist also looks at the overall appearance and arrangement of the cells, as well as any signs of invasion into surrounding tissue.^[4]

Malignant meningiomas can spread to other areas of the central nervous system through cerebrospinal fluid (CSF), which is the liquid that circulates around the brain and spinal cord. Grade 3 meningiomas have irregular cells and are likely to invade the brain or spread to other organs in the body, although this is rare. Grade 2 meningiomas can invade surrounding tissue, including nearby bone tissue.^[3][10]

Additional Diagnostic Considerations

Sometimes meningiomas are discovered accidentally when brain scans are done for other reasons, such as after a head injury or when investigating unrelated symptoms. These tumors found by chance are called incidental findings. When a meningioma is found this way and is small and not causing symptoms, doctors may recommend watching it over time rather than immediate treatment.^[8][18]

Diagnosing a malignant meningioma can be challenging for several reasons. These tumors grow slowly, so symptoms may not appear until the tumor is quite large. Also, symptoms can vary widely depending on where in the brain the tumor is located. A tumor pressing on the area that controls vision will cause different symptoms than one pressing on areas controlling balance or hearing. This variability means doctors must be thorough in their evaluation.^[1]

Diagnostics for Clinical Trial Qualification

When patients with malignant meningioma consider participating in clinical trials, specific diagnostic tests are often required to determine eligibility. Clinical trials are research studies that test new treatments, and they have strict criteria for who can enroll. Understanding what tests are needed can help you prepare if you’re considering this option.^[13]

First and foremost, patients must have a confirmed tissue diagnosis from a neuropathologist showing that their tumor is indeed a Grade 3 malignant meningioma. The pathology report documenting the tumor grade and subtype is essential for trial enrollment. Some trials may also require specific molecular testing or genetic analysis of the tumor tissue to look for particular mutations or characteristics that the experimental treatment targets.^[3][10]

Baseline imaging studies are nearly always required before starting a clinical trial. You will typically need a recent MRI scan (usually within a few weeks of enrollment) that clearly shows the size and location of your tumor. This baseline scan serves as a comparison point so researchers can measure whether the experimental treatment is working by comparing future scans to see if the tumor is shrinking, staying stable, or growing.^[13]

Clinical trials often require comprehensive blood tests to assess your overall health and organ function. These tests check how well your kidneys, liver, and bone marrow are working, as many treatments can affect these organs. Blood counts are especially important because some treatments can lower white blood cells, red blood cells, or platelets. Your healthcare team needs to know your starting values before treatment begins.^[13]

Performance status assessment is another standard requirement. This is a measure of how well you can perform daily activities and how much the disease is affecting your life. Doctors use standardized scales to rate your functional abilities. Most clinical trials only accept patients who are well enough to care for themselves and be active for at least part of the day, though requirements vary by study.^[13]

Some clinical trials for malignant meningioma may require additional specialized tests depending on what treatment is being studied. For example, if the trial involves a drug that targets blood vessel growth, you might need tests to evaluate your cardiovascular health. If the treatment being tested is an immunotherapy, tests of your immune system function might be required.^[13]

Documentation of prior treatments is also critical for clinical trial enrollment. You’ll need records showing what treatments you’ve already received, including surgery, radiation therapy, and any medications. Trials often specify whether they’re looking for patients who are newly diagnosed, have recurrent disease, or have tried and failed other treatments. Having complete medical records ready can speed up the enrollment process.^[6]